Nocardiosis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Medical Therapy== | ==Medical Therapy== | ||
Nocardiosis requires at least 6 months of treatment, preferably with [[co-trimoxazole]] or high doses of [[sulfonamide]]s. In patients who don’t respond to sulfonamide treatment, other drugs, such as [[ampicillin]], [[erythromycin]], or [[minocycline]], may be added. Treatment also includes surgical drainage of [[abscess]]es and excision of necrotic tissue. The acute phase requires complete bed rest; as the patient improves, activity can increase. A new combination drug therapy ([[sulfonamide]], [[ceftriaxone]], and [[amikacin]]) has also shown promise. | Nocardiosis requires at least 6 months of treatment, preferably with [[co-trimoxazole]] or high doses of [[sulfonamide]]s. In patients who don’t respond to sulfonamide treatment, other drugs, such as [[ampicillin]], [[erythromycin]], or [[minocycline]], may be added. Treatment also includes surgical drainage of [[abscess]]es and excision of necrotic tissue. The acute phase requires complete bed rest; as the patient improves, activity can increase. A new combination drug therapy ([[sulfonamide]], [[ceftriaxone]], and [[amikacin]]) has also shown promise. | ||
Revision as of 19:45, 10 December 2012
|
Nocardiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Nocardiosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Nocardiosis medical therapy |
|
Risk calculators and risk factors for Nocardiosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
Nocardiosis requires at least 6 months of treatment, preferably with co-trimoxazole or high doses of sulfonamides. In patients who don’t respond to sulfonamide treatment, other drugs, such as ampicillin, erythromycin, or minocycline, may be added. Treatment also includes surgical drainage of abscesses and excision of necrotic tissue. The acute phase requires complete bed rest; as the patient improves, activity can increase. A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has also shown promise.